<span style="margin-left: 0em;">AKT inhibitor</span> <span style="margin-left: 1em;">capivasertib based treatment</span> <span style="margin-left: 2em;">capivasertib plus paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">ipatasertib based treatment</span> <span style="margin-left: 2em;">ipatasertib plus paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">placebo plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">atezolizumab based treatment</span> <span style="margin-left: 3em;">atezolizumab plus nab-paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">atezolizumab plus paclitaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">poly ADP-ribose polymerase (PARP) inhibitor</span> <span style="margin-left: 1em;">veliparib plus paclitaxel plus carboplatin <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (11) progression or deaths (PFS) (10) objective responses (ORR) (8) DOR (5) events or deaths (EFS) (3) PFS (extension) (2) pCR (2) AE leading to treatment discontinuation (any grade) (7) TRAE leading to death (grade 5) (3) AE (any grade) (2) TRAE (any grade) (2) TRAE (grade 3-4) (2) AE (grade 3-4) (2) SAE (any grade) (1) AE leading to death (grade 5) (1) STRAE (any grade) (1) Nausea TRAE (grade 3-4) (1) Colitis TRAE (grade 3-4) (1) Increased ALT TRAE (grade 3-4) (1) Anaemia TRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (1) Hyperthyroidism TRAE (grade 3-4) (1) Fatigue TRAE (grade 3-4) (1) Pneumonitis TRAE (grade 3-4) (1) Neutropenia TRAE (grade 3-4) (1) Leucopenia TRAE (grade 3-4) (1) Alopecia TRAE (grade 3-4) (1) Severe skin reaction TRAE (grade 3-4) (1) Peripheral oedema AE (grade 3-4) (2) Vomiting AE (grade 3-4) (1) Constipation AE (grade 3-4) (1) Abdominal pain AE (grade 3-4) (1) Fatigue AE (grade 3-4) (1) Headache AE (grade 3-4) (1) Decreased appetite AE (grade 3-4) (1) Dyspnoea AE (grade 3-4) (1) Cough AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (1) Rash AE (grade 3-4) (1) Increased ALT AE (grade 3-4) (1) Increase AST AE (grade 3-4) (1) Pyrexia AE (grade 3-4) (1) Chills AE (grade 3-4) (1) Back pain AE (grade 3-4) (1) Hypertension AE (grade 3-4) (1) Hypothyroidism AE (grade 3-4) (1) Dysphonia AE (grade 3-4) (1) Arthralgia AE (grade 3-4) (1) Stomatitis AE (grade 3-4) (1) Mucosal inflammation AE (grade 3-4) (1) Hyperthyroidism AE (grade 3-4) (1) Dysgeusia AE (grade 3-4) (1) Anaemia AE (grade 3-4) (1) Thrombocytopenia AE (grade 3-4) (1) Neutropenia AE (grade 3-4) (1) Dizziness AE (grade 3-4) (1) Weight decreased AE (grade 3-4) (1) Colitis AE (grade 3-4) (1) Leucopenia AE (grade 3-4) (1) Pneumonitis AE (grade 3-4) (1) Sepsis AE (grade 3-4) (1) Acute kidney injury AE (grade 3-4) (1) Peripheral neuropathy AE (grade 3-4) (1) Myalgia AE (grade 3-4) (1) hepatitis (Autoimmune) AE (grade 3-4) (1) Alopecia AE (grade 3-4) (1) Pruritus AE (grade 3-4) (1) Nausea AE (grade 3-4) (1) Paraesthesia AE (grade 3-4) (1) Cardiomyopathy AE (grade 3-4) (1) Myopathy AE (grade 3-4) (1) Adrenal insufficiency AE (grade 3-4) (1) Pericarditis AE (grade 3-4) (1) Pneumonia AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
2 IMpassion-130 (all population), 2018
IMpassion-130 (PDL1>1%), 2018 2 IMpassion-131 (PD-L1 > 1%), 2020
IMpassion-131 (all population), 2020 3 KEYNOTE-355 (all population), 2020
KEYNOTE-355 (CPS>1), 2020
KEYNOTE-355 (CPS>10), 2020 2 PAKT (all population), 2020
PAKT (PIK3CA/AKT1/PTEN-altered), 2020 1 LOTUS, 2017 1 BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 2018 atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel
atezolizumab plus nab-paclitaxel better
0.73 [0.57; 0.94] 0.73 [0.57;0.94]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel
atezolizumab plus nab-paclitaxel better
0.73 [0.57; 0.94] atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel
1.45 [0.90; 2.33] 1.45 [0.90;2.33]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel
1.45 [0.90; 2.33] atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel
1.02 [0.62; 1.67] 1.02 [0.62;1.67]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel
1.02 [0.62; 1.67] atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC
0.96 [0.80; 1.15] 0.96 [0.80;1.15]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC
0.96 [0.80; 1.15] atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC)
atezolizumab plus nab-paclitaxel better
0.81 [0.70; 0.94] 0.81 [0.70;0.94]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC)
atezolizumab plus nab-paclitaxel better
0.81 [0.70; 0.94] atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin
0.99 [0.57; 1.72] 0.99 [0.57;1.72]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin
0.99 [0.57; 1.72] atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel
atezolizumab plus nab-paclitaxel better
1.37 [1.07; 1.77] 1.37 [1.07;1.77]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel
atezolizumab plus nab-paclitaxel better
1.37 [1.07; 1.77] atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel
capivasertib plus paclitaxel better
1.99 [1.21; 3.26] 1.99 [1.21;3.26]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel
capivasertib plus paclitaxel better
1.99 [1.21; 3.26] atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel
1.40 [0.84; 2.33] 1.40 [0.84;2.33]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel
1.40 [0.84; 2.33] atezolizumab plus paclitaxel vs. pembrolizumab plus SoC
pembrolizumab plus SoC better
1.31 [1.04; 1.66] 1.31 [1.04;1.66]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC
pembrolizumab plus SoC better
1.31 [1.04; 1.66] atezolizumab plus paclitaxel vs. Standard of Care (SoC)
1.12 [0.91; 1.37] 1.12 [0.91;1.37]atezolizumab plus paclitaxel vs. Standard of Care (SoC)
1.12 [0.91; 1.37] atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin
1.36 [0.77; 2.40] 1.36 [0.77;2.40]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin
1.36 [0.77; 2.40] capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel
0.69 [0.43; 1.11] 0.69 [0.43;1.11]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel
0.69 [0.43; 1.11] capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel
capivasertib plus paclitaxel better
0.50 [0.31; 0.83] 0.50 [0.31;0.83]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel
capivasertib plus paclitaxel better
0.50 [0.31; 0.83] capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel
0.70 [0.37; 1.35] 0.70 [0.37;1.35]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel
0.70 [0.37; 1.35] capivasertib plus paclitaxel vs. pembrolizumab plus SoC
0.66 [0.42; 1.05] 0.66 [0.42;1.05]capivasertib plus paclitaxel vs. pembrolizumab plus SoC
0.66 [0.42; 1.05] capivasertib plus paclitaxel vs. Standard of Care (SoC)
capivasertib plus paclitaxel better
0.56 [0.36; 0.88] 0.56 [0.36;0.88]capivasertib plus paclitaxel vs. Standard of Care (SoC)
capivasertib plus paclitaxel better
0.56 [0.36; 0.88] capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin
0.69 [0.34; 1.37] 0.69 [0.34;1.37]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin
0.69 [0.34; 1.37] ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel
0.98 [0.60; 1.61] 0.98 [0.60;1.61]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel
0.98 [0.60; 1.61] ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel
0.72 [0.43; 1.20] 0.72 [0.43;1.20]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel
0.72 [0.43; 1.20] ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel
1.42 [0.74; 2.73] 1.42 [0.74;2.73]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel
1.42 [0.74; 2.73] ipatasertib plus paclitaxel vs. pembrolizumab plus SoC
0.94 [0.58; 1.52] 0.94 [0.58;1.52]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC
0.94 [0.58; 1.52] ipatasertib plus paclitaxel vs. Standard of Care (SoC)
0.80 [0.50; 1.28] 0.80 [0.50;1.28]ipatasertib plus paclitaxel vs. Standard of Care (SoC)
0.80 [0.50; 1.28] ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin
0.98 [0.48; 1.98] 0.98 [0.48;1.98]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin
0.98 [0.48; 1.98] pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel
1.04 [0.87; 1.26] 1.04 [0.87;1.26]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel
1.04 [0.87; 1.26] pembrolizumab plus SoC vs. atezolizumab plus paclitaxel
pembrolizumab plus SoC better
0.76 [0.60; 0.96] 0.76 [0.60;0.96]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel
pembrolizumab plus SoC better
0.76 [0.60; 0.96] pembrolizumab plus SoC vs. capivasertib plus paclitaxel
1.51 [0.95; 2.41] 1.51 [0.95;2.41]pembrolizumab plus SoC vs. capivasertib plus paclitaxel
1.51 [0.95; 2.41] pembrolizumab plus SoC vs. ipatasertib plus paclitaxel
1.06 [0.66; 1.72] 1.06 [0.66;1.72]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel
1.06 [0.66; 1.72] pembrolizumab plus SoC vs. Standard of Care (SoC)
pembrolizumab plus SoC better
0.85 [0.76; 0.95] 0.85 [0.76;0.95]pembrolizumab plus SoC vs. Standard of Care (SoC)
pembrolizumab plus SoC better
0.85 [0.76; 0.95] pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin
1.04 [0.60; 1.78] 1.04 [0.60;1.78]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin
1.04 [0.60; 1.78] Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel
atezolizumab plus nab-paclitaxel better
1.23 [1.06; 1.42] 1.23 [1.06;1.42]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel
atezolizumab plus nab-paclitaxel better
1.23 [1.06; 1.42] Standard of Care (SoC) vs. atezolizumab plus paclitaxel
0.90 [0.73; 1.10] 0.90 [0.73;1.10]Standard of Care (SoC) vs. atezolizumab plus paclitaxel
0.90 [0.73; 1.10] Standard of Care (SoC) vs. capivasertib plus paclitaxel
capivasertib plus paclitaxel better
1.78 [1.13; 2.79] 1.78 [1.13;2.79]Standard of Care (SoC) vs. capivasertib plus paclitaxel
capivasertib plus paclitaxel better
1.78 [1.13; 2.79] Standard of Care (SoC) vs. ipatasertib plus paclitaxel
1.25 [0.78; 2.00] 1.25 [0.78;2.00]Standard of Care (SoC) vs. ipatasertib plus paclitaxel
1.25 [0.78; 2.00] Standard of Care (SoC) vs. pembrolizumab plus SoC
pembrolizumab plus SoC better
1.18 [1.05; 1.31] 1.18 [1.05;1.31]Standard of Care (SoC) vs. pembrolizumab plus SoC
pembrolizumab plus SoC better
1.18 [1.05; 1.31] Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin
1.22 [0.72; 2.07] 1.22 [0.72;2.07]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin
1.22 [0.72; 2.07] veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel
1.01 [0.58; 1.74] 1.01 [0.58;1.74]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel
1.01 [0.58; 1.74] veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel
0.73 [0.42; 1.29] 0.73 [0.42;1.29]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel
0.73 [0.42; 1.29] veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel
1.46 [0.73; 2.92] 1.46 [0.73;2.92]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel
1.46 [0.73; 2.92] veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel
1.02 [0.51; 2.08] 1.02 [0.51;2.08]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel
1.02 [0.51; 2.08] veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC
0.96 [0.56; 1.65] 0.96 [0.56;1.65]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC
0.96 [0.56; 1.65] veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC)
0.82 [0.48; 1.39] 0.82 [0.48;1.39]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC)
0.82 [0.48; 1.39] Standard of Care (SoC) placebo plus SoC atezolizumab plus nab-paclitaxel atezolizumab plus paclitaxel pembrolizumab plus SoC capivasertib plus paclitaxel ipatasertib plus paclitaxel veliparib plus paclitaxel plus carboplatin direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) placebo plus SoC atezolizumab plus nab-paclitaxel atezolizumab plus paclitaxel pembrolizumab plus SoC capivasertib plus paclitaxel ipatasertib plus paclitaxel veliparib plus paclitaxel plus carboplatin Standard of Care (SoC) --- NA 1.23 1.06; 1.420.90 0.73; 1.101.18 1.05; 1.311.78 1.13; 2.791.25 0.78; 2.001.22 0.72; 2.07placebo plus SoC NA --- NA NA NA NA NA NA atezolizumab plus nab-paclitaxel 0.81 0.70; 0.94NA --- 0.73 0.57; 0.940.96 0.80; 1.151.45 0.90; 2.331.02 0.62; 1.670.99 0.57; 1.72atezolizumab plus paclitaxel 1.12 0.91; 1.37NA 1.37 1.07; 1.77--- 1.31 1.04; 1.661.99 1.21; 3.261.40 0.84; 2.331.36 0.77; 2.40pembrolizumab plus SoC 0.85 0.76; 0.95NA 1.04 0.87; 1.260.76 0.60; 0.96--- 1.51 0.95; 2.411.06 0.66; 1.721.04 0.60; 1.78capivasertib plus paclitaxel 0.56 0.36; 0.88NA 0.69 0.43; 1.110.50 0.31; 0.830.66 0.42; 1.05--- 0.70 0.37; 1.350.69 0.34; 1.37ipatasertib plus paclitaxel 0.80 0.50; 1.28NA 0.98 0.60; 1.610.72 0.43; 1.200.94 0.58; 1.521.42 0.74; 2.73--- 0.98 0.48; 1.98veliparib plus paclitaxel plus carboplatin 0.82 0.48; 1.39NA 1.01 0.58; 1.740.73 0.42; 1.290.96 0.56; 1.651.46 0.73; 2.921.02 0.51; 2.08---
pathologies: 269,60,143
- treatments: 1252
result logic